title: [Biomarker development by cancer proteomics].
abstract: Cancer is a genetically and clinically diverse disease, and biomarkers are required to optimize the therapeutic strategies. Proteome is a functional translation of genome, directly regulating cancer phenotypes. Biomarker studies have been conducted by the proteomic approach. By the proteomic approach, we developed a novel prognostic biomarker in gastrointestinal stromal tumor(GIST). In GIST, adjuvant imatinib mesylate after resection improved recurrence-free survival. A prognostic biomarker is required to select the patients for the treatment with imatinib mesylate. Proteomic approach using two-dimensional difference gel electrophoresis(2D-DIGE) identified pfetin as a biomarker for favorable prognosis. Multi-institutional validation study by immunohistochemistry established the prognostic values of pfetin in GIST. Pfetin will be applicable for a novel prognostic modality.
authors.affiliation: Division of Pharmacoproteomics, National Cancer Center Research Institute.
authors.forename: Tadashi
authors.initials: T
authors.lastname: Kondo
mesh_terms: D014408:Biomarkers, Tumor / Q000032:analysis*; D005770:Gastrointestinal Neoplasms / Q000175:diagnosis*; D046152:Gastrointestinal Stromal Tumors / Q000175:diagnosis*; D006801:Humans; D011379:Prognosis; D040901:Proteomics
chemical_list: D014408:Biomarkers, Tumor